Study of ZG005 in Combination With Paclitaxel＋Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma
This is a multicenter, open-label phase I/II study for the first-line treatment of advanced cervical cancer.
Cervical Carcinoma
DRUG: ZG005 Powder for Injection|DRUG: Paclitaxel|BIOLOGICAL: Bevacizumab|DRUG: Cisplatin|DRUG: Carboplatin
Dose Limiting Toxicity (DLT), Up to 2 years|Objective Response Rate (ORR), ORR was defined as the percentage of the participants in the analysis population who have a Complete Response or a Partial Response. The ORR per RECIST 1.1 as assessed by Investigator is presented., Up to 2 years
This is a multicenter, open-label phase I/II study for the first-line treatment of advanced cervical cancer.